Fresolimumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | TGF beta 1, 2 and 3 |
Clinical data | |
ATC code | none |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | 948564-73-6 |
ChemSpider | none |
KEGG | D09620 |
Chemical and physical data | |
Formula | C6392H9926N1698O2026S44 |
Molar mass | 144.4 kg/mol |
(what is this?) (verify) |
Fresolimumab (GC1008) is a human monoclonal antibody[1] and an immunomodulator. It is intended for the treatment of idiopathic pulmonary fibrosis (IPF), focal segmental glomerulosclerosis, and cancer[2][3] (kidney cancer and melanoma).
It binds to and inhibits all isoforms of the protein transforming growth factor beta (TGF-β).[2]
History
Fresolimumab was discovered by Cambridge Antibody Technology (CAT) scientists[4] and was one of a pair of candidate drugs that were identified for the treatment of the fatal condition scleroderma. CAT chose to co-develop the two drugs metelimumab (CAT-192) and fresolimumab with Genzyme. During early development, around 2004, CAT decided to drop development of metelimumab in favour of fresolimumab.[5]
In February 2011 Sanofi-Aventis agreed to buy Genzyme for US$ 20.1 billion.[6]
As of June 2011 the drug was being tested in humans (clinical trials) against IPF, renal disease, and cancer.[7][8] On 13 August 2012, Genzyme applied to begin a Phase 2 clinical trial in primary focal segmental glomerulosclerosis[9] comparing fresolimumab versus placebo.
As of July 2014, Sanofi-Aventis continue to list fresolimumab in their research and development portfolio under Phase II development.[10]
References
- ↑ WHO Drug Information
- 1 2 National Cancer Institute: Fresolimumab
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council – Fresolimumab
- ↑ Grütter, Christian; Wilkinson, Trevor; Turner, Richard; Podichetty, Sadhana; Finch, Donna; McCourt, Matthew; Loning, Scott; Jermutus, Lutz; Grütter, Markus G. (2008-12-23). "A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions". Proceedings of the National Academy of Sciences. 105 (51): 20251–20256. doi:10.1073/pnas.0807200106. ISSN 0027-8424. PMC 2600578. PMID 19073914.
- ↑ http://www.independent.co.uk/news/business/news/cat-may-abandon-skin-drug-after-trial-results-disappoint-569445.html
- ↑ http://www.bbc.co.uk/news/business-12477750
- ↑ http://www.genengnews.com/gen-news-highlights/scientists-trigger-white-fat-to-become-brown-fat-like-to-treat-obesty-and-type-2-diabetes/81245389/
- ↑ Clinicaltrials.gov for Fresolimumab
- ↑ http://clinicaltrials.gov/show/NCT01665391
- ↑ http://en.sanofi.com/rd/rd_portfolio/rd_portfolio.aspx